NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
ABSTRACT Background GBA1 variants cause Gaucher disease (GD) in biallelic forms and increase Parkinson’s disease (PD) risk in heterozygous carriers. Carriers of ‘severe’ or ‘mild’ variants (causing GD type 1 or types 2-3) can enroll in clinical trials, whereas those with ‘unknown’ variants are typically excluded. Objectives We assessed the contribution of ‘unknown’ variants to PD risk and their relevance for trial stratification. Methods We meta-analyzed 34 case–control studies (24,060 PD cases, 14,465 controls). Odds ratios (OR) were estimated using random-effects models and stratified by the American College of Medical Genetics (ACMG) criteria. Results ‘Unknown’ variants also classified as variants of uncertain significance (VUS) per ACMG criteria were associated with PD (OR=1.59, 95%CI:1.25–2.02; I 2 =0%). VUS + likely pathogenic + pathogenic also showed association (OR=1.63, 95%CI:1.28–2.06; I 2 =0%). Conclusions ‘Unknown’ GBA1 variants may be considered in clinical trials if also classified as VUS, likely pathogenic, or pathogenic per ACMG criteria.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.